Advertisement

Zeitschrift für Rheumatologie

, Volume 77, Issue 6, pp 460–468 | Cite as

Was der Rheumatologe vom Gastroenterologen lernen kann

  • S. Fischer
  • C. Beyer
  • M. F. Neurath
Leitthema

Zusammenfassung

Hintergrund

Chronisch entzündliche Erkrankungen (CED) stellen komplexe Krankheitsbilder dar, welche aufgrund ihrer vielfältigen Manifestationen im interdisziplinären Kontext betrachtet werden sollten.

Ziele der Arbeit

Diese Arbeit bietet Überblick über aktuelle Entwicklungen bei CED.

Methoden

Es wurde eine Literaturrecherche in PubMed durchgeführt.

Ergebnisse

Sich überschneidende pathophysiologische Regelkreisläufe von CED führen teilweise zu gemeinsamen Therapieansätzen; es bestehen jedoch auch spezifische Unterschiede in der Therapie.

Schlussfolgerung

Aufgrund zahlreicher extraintestinaler Organmanifestationen bedürfen CED eines interdisziplinären Therapieansatzes.

Schlüsselwörter

Chronisch entzündliche Darmerkrankungen Mikrobiom Calprotectin Arthritis Glukokortikoide 

What rheumatologists can learn from gastroenterologists

Abstract

Background

Chronic inflammatory diseases are complex disorders, which due to their multitude of manifestations require interdisciplinary treatment.

Objective

The aim of this article is to provide a brief overview of current strategies and innovations for chronic inflammatory bowel diseases.

Methods

A literature search was carried out in PubMed.

Results

Shared pathophysiological pathways in chronic inflammatory diseases sometimes lead to common targets in treatment; however, there are also relevant specific differences with respect to treatment.

Conclusion

Due to the many extraintestinal organ manifestations, chronic inflammatory bowel diseases require interdisciplinary treatment.

Keywords

Chronic inflammatory bowel diseases Microbiota Calprotectin Arthritis Glucocorticoids 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

S. Fischer, C. Beyer und M. F. Neurath geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Ardizzone S et al (2011) Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 9(6):483–489.e3CrossRefPubMedGoogle Scholar
  2. 2.
    Frøslie KF, Jahnsen J, Moum BA, Vatn MH, IBSEN Group (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133(2):412–422CrossRefPubMedGoogle Scholar
  3. 3.
    Colombel JF et al (2011) Early mucosal healing with Infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141(4):1194–1201CrossRefPubMedGoogle Scholar
  4. 4.
    Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18(10):1542–1551PubMedGoogle Scholar
  5. 5.
    Salmi M, Andrew DP, Butcher EC, Jalkanen S (1995) Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 181(1):137–149CrossRefPubMedGoogle Scholar
  6. 6.
    Demetter P et al (2005) Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 64(2):321–324CrossRefPubMedGoogle Scholar
  7. 7.
    McEniff N, Eustace S, McCarthy C, O’Malley M, O’Morain CA, Hamilton S (1995) Asymptomatic sacroiliitis in inflammatory bowel disease. Assessment by computed tomography. Clin Imaging 19(4):258–262CrossRefPubMedGoogle Scholar
  8. 8.
    Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42(3):387–391CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Walsham NE, Sherwood RA (2016) Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol 9:21–29PubMedPubMedCentralGoogle Scholar
  10. 10.
    Gisbert JP et al (2009) Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 15(8):1190–1198CrossRefPubMedGoogle Scholar
  11. 11.
    Panaccione R et al (2014) Combination therapy with Infliximab and Azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146(2):392–400.e3CrossRefPubMedGoogle Scholar
  12. 12.
    Carbonnel F et al (2016) Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 150(2):380–388.e4CrossRefPubMedGoogle Scholar
  13. 13.
    Sandborn WJ et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5):1088–1094CrossRefPubMedGoogle Scholar
  14. 14.
    Panaccione R et al (2015) Briakinumab for treatment of Crohn’s disease: results of a randomized trial. Inflamm Bowel Dis 21(6):1329–1340PubMedPubMedCentralGoogle Scholar
  15. 15.
    Feagan BG et al (2017) Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389(10080):1699–1709CrossRefPubMedGoogle Scholar
  16. 16.
    Hueber W et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12):1693–1700CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Vermeire S et al (2014) Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384(9940):309–318CrossRefPubMedGoogle Scholar
  18. 18.
    Vermeire S et al (2017) Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 390(10090):135–144CrossRefPubMedGoogle Scholar
  19. 19.
    Sandborn WJ et al (2017) Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study. Gut.  https://doi.org/10.1136/gutjnl-2016-313457 PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Sandborn WJ et al (2016) Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374(18):1754–1762CrossRefPubMedGoogle Scholar
  21. 21.
    Peyrin-Biroulet L, Christopher R, Behan D, Lassen C (2017) Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev 16(5):495–503CrossRefPubMedGoogle Scholar
  22. 22.
    Panés J et al (2017) Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut 66(6):1049–1059CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Sandborn WJ et al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376(18):1723–1736CrossRefPubMedGoogle Scholar
  24. 24.
    Vermeire S et al (2017) Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389(10066):266–275CrossRefPubMedGoogle Scholar
  25. 25.
    Popp V et al (2017) Rectal delivery of a DNAzyme that specifically blocks the transcription factor GATA3 and reduces colitis in mice. Gastroenterology 152(1):176–192.e5CrossRefPubMedGoogle Scholar
  26. 26.
    Atreya R et al (2016) Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis. J Crohns Colitis 10(11):1294–1302CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Panés J et al (2016) Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388(10051):1281–1290CrossRefPubMedGoogle Scholar
  28. 28.
    Atreya R et al (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 20(3):313–318CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rath T, Bojarski C, Neurath MF, Atreya R (2017) Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn’s disease. Gastrointest Endosc 86(2):406–408CrossRefPubMedGoogle Scholar
  30. 30.
    West NR et al (2017) Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 23(5):579–589PubMedPubMedCentralGoogle Scholar
  31. 31.
    Tew GW et al (2016) Association between response to Etrolizumab and expression of integrin αE and granzyme A in colon biopsies of patients with ulcerative colitis. Gastroenterology 150(2):477–487.e9CrossRefPubMedGoogle Scholar
  32. 32.
    de Souza HSP, Fiocchi C, Iliopoulos D (2017) The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 14(12):739–749CrossRefPubMedGoogle Scholar
  33. 33.
    Olivera P, Danese S, Peyrin-Biroulet L (2017) Next generation of small molecules in inflammatory bowel disease. Gut 66(2):199–209CrossRefPubMedGoogle Scholar
  34. 34.
    Danese S (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61(6):918–932CrossRefPubMedGoogle Scholar
  35. 35.
    Coskun M, Vermeire S, Nielsen OH (2017) Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci 38(2):127–142CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Medizinische Klinik 1Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-NürnbergErlangenDeutschland

Personalised recommendations